CANBridge Life Sciences, VoxelCloud and Huajiao Live Video have closed funding rounds.
CANbridge Life Sciences raises $25m Series B
CANbridge Life Sciences, a Beijing, China-based clinical-stage bio-pharmaceutical company focused on developing Western drug candidates in China and North Asia, has closed a $25 million Series B round led by Lapam Capital, with participation from Qiming Venture Partners, Yuanming Capital, Yanyuan Capital, Biossom Investment Management and Wuxi AppTec.
The company, which has raised over $40 million across Series A and B financing rounds in total, has plans for additional strategic transactions in 2017. It intends to use the funds for the clinical trial development of its two lead compounds, CAN008 and CAN017, in China.
CAN008, a fully-human fusion onco-immunotherapy, is currently in a Phase I/II for the treatment of glioblastoma multiforme (GBM), in Taiwan. CANbridge plans to initiate a Phase II CAN008 GBM trial in China in 2018. CAN017, an antibody inhibitory onco-immunotherpy, will target esophageal squamous cell cancer (ESCC), the prevalent form of oesophagal cancer in Asia.
Led by James Xue, PhD, Chairman and CEO, CANbridge is a clinical stage biopharmaceutical company accelerating development and commercialisation of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan).
Sequoia Capital leads $8m Series A in VoxelCloud
Sequoia Capital has led a $8 million series A round in Los Angeles-based AI startup VoxelCloud, which maintains research teams in Shanghai and Suzhou. VoxelCloud provides automated medical image analysis services.
VoxelCloud was founded in 2015 by the team Demetri Terzopoulos, Liang Jianming, and Ding Xiaowei. It previously raised $5.5 millon in an angel round in September 2016.
Proceeds from this Series A round will expand its cope of medical image analysis services, and establish further collaboration with medical institutions in China and the US.
In an official statement, a Sequoia representative said, “We have long believed in the vast potential of artificial intelligence in medicine. Our partnership with VoxelCloud is driven by this vision. We are excited to witness this innovation and be part of it through our investment in VoxelCloud.”
The company makes use of AI and cloud-computing technology to provide personalised medical image analysis by building medical image knowledge graph based on medical semantics and multiple artificial intelligence models.
Its products have provided end-to-end solutions for lung cancer, diabetic retinopathy, coronary heart disease and liver disease.
Tian Ge Interactive invests $14m in Huajiao Live Video
Hong Kong-listed Tian Ge Interactive Holdings Ltd., a Hangzhou-based live social video platform, have made an RMB100 million ($14 million) investment in Huajiao Live Video, a live video streaming mobile app backed by Qihoo 360 Technology Co. Ltd.
The transaction also sees the two companies forming a strategic partnership for a term of two years to develop their live video streaming business, advanced technology, business model and online live streaming product. This will see Tian Ge participate in the research, operation, and marketing of Huajiao Live Video.
Officially launched in 2015, Huajiao raised RMB300 million ($45 million) in a series A round from Chinese state-owned entity Zhongshoujian, with Qihoo 360 injecting RMB60 million ($8 million).